Avalo Q1 net loss $13.1M; cash $125M; Phase 2 HS data expected 2026

Avalo Therapeutics, Inc.

2025-Q1 EPS reported -$1.25

Net loss $13.1M ($1.25/shr) vs $121.3M in Q1 2024; prior-year included warrant and acquisition charges.
Cash and equivalents $125M at March 31, 2025; runway into 2027, extendable to 2028 by delaying new indications.
Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa on track; topline data expected in 2026.
Mike Heffernan appointed Chairman of the Board.
R&D expenses $9.1M (+$7M YoY) driven by LOTUS trial; G&A $5.5M (+$2.4M YoY) on stock compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.